Raptiva Labeling Should Require Monitoring For Thrombocytopenia – Cmte.
Executive Summary
Genentech/Xoma Raptiva labeling should require platelet count monitoring to minimize the risk of thrombocytopenia, FDA Dermatologic & Ophthalmic Drugs Advisory Committee recommended
You may also be interested in...
Genentech Raptiva To Undergo 5,000-Patient Postmarketing Safety Study
Genentech will conduct a 5,000-patient study of the incidence of adverse events associated with Raptiva (efalizumab) as a condition of FDA approval of the psoriasis treatment
Genentech Raptiva To Undergo 5,000-Patient Postmarketing Safety Study
Genentech will conduct a 5,000-patient study of the incidence of adverse events associated with Raptiva (efalizumab) as a condition of FDA approval of the psoriasis treatment
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive